SARS-CoV-2 Rapid Antigen Test Nasal Quick Reference Guide

Document version: Initial version | Revision date: January, 2021

Important Safety Information

⚠️ Warning! Follow all health and safety regulations.

Document Information

Manufacturer: SD Biosensor, Inc.

C-4th&5th, 16, Deogyeong-daero 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA

Authorized Representative: MT Promedt Consulting GmbH, Altenhofstrasse 80, D-66386 St. Ingbert, Germany

Distributed by: Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim, Germany

www.roche.com

For in vitro diagnostics use only. Not for self testing.

© 2020. All rights reserved.

Document Code: 0 9368221001 (01) 2021-01 EN

1 Preparing for a test

  1. Carefully read the Instructions for Use for the SARS-CoV-2 Rapid Antigen Test Nasal.
  2. Check the expiry date ? on the back of the foil pouch. Do not use the test if the expiry date has passed.
  3. Open the foil pouch and remove the test device and the desiccant package.
  4. Ensure that the test device is undamaged and that the desiccant status indicator shows valid (yellow).

2 Collecting and preparing nasal sample

  1. Tilt the patient's head slightly back (approx. 70° angle).[Diagram: Patient's head tilted back]
  2. Insert sterile swab into the nostril with the most secretion.
  3. Insert the sterile swab into the nostril with the most secretion. While rotating the swab, insert the swab 2 cm (slightly less than 1 inch) parallel to the palate (not upwards) towards the throat into the nostril until resistance is met at turbinates. Do not apply pressure.[Diagram: Swab inserted into nostril, parallel to palate]
  4. Rotate the swab 4 times for about 15 seconds against the nasal wall and remove it from the nostril.[Diagram: Rotating swab against nasal wall, 4x]
  5. Repeat step 3 to 4 with the same swab in the other nostril.[Diagram: Swab used for both left and right nostrils]

    Note: Samples must be collected from both nostrils using the same swab.

  6. Insert the swab into an extraction buffer tube. While squeezing the buffer tube, stir the swab more than 10 times.[Diagram: Swab in buffer tube, stirring >10 times]
  7. Remove the swab while squeezing the sides of the tube to extract the liquid from the swab.[Diagram: Squeezing buffer tube to extract liquid from swab]

    WARNING! Failure to squeeze the tube can lead to incorrect results due to excess buffer in the swab.

  8. Press the nozzle cap tightly onto the tube. Continue with 3 Performing a test.[Diagram: Nozzle cap attached to buffer tube]

3 Performing a test

  1. Place the test device on a flat surface and apply 4 drops of extracted sample at a 90° angle to the specimen well of the test device.[Diagram: Applying 4 drops ? to the specimen well]
  2. Read the test result at 15 to 30 min.[Diagram: Timer icon indicating 15-30 minute reading window ⏱️]

    WARNING! Risk of incorrect results. Do not read the test result after 30 min.

4 Interpreting results

A colored line appears in the top section of the result window to show that the test is working properly. This is the control line (C). Even if the control line is faint, the test should be considered to have been performed properly. If no control line is visible the test is invalid.

In case of a positive result, a colored line appears in the lower section of the result window. This is the test line (T). Even if the test line is very faint or not uniform, the test result should be interpreted as a positive result.

[Diagram: Test device showing Control line (C) and Test line (T) indicators]

Result Interpretation:

Note: The presence of any test line no matter how faint, together with a control line, should be considered as a positive result. For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination, and other findings.

5 Performing a QC (as required)

  1. Put the positive or negative control swab into an extraction buffer tube. Stir the swab more than 5 times.[Diagram: Control swab in buffer tube, stirring >5 times ?]
  2. Remove the swab while squeezing the sides of the tube to extract the liquid from the swab.[Diagram: Squeezing buffer tube to extract liquid from control swab ?]
  3. Press the nozzle cap tightly onto the tube.
  4. Place the test device on a flat surface and apply 3 drops of extracted sample at a 90° angle to the specimen well of the test device.[Diagram: Applying 3 drops ? to the specimen well]
  5. Read the test result at 15 to 30 min as described in 4 Interpreting results.[Diagram: Timer icon indicating 15-30 minute reading window ⏱️]

    WARNING! Risk of incorrect results. Do not read the test result after 30 min.

Models: SARS-CoV-2 Rapid Antigen Test Nasal

File Info : application/pdf, 1 Pages, 721.84KB

Rapid-Antigen-Test-Nasal-QRG

References

Adobe PDF Library 15.0 Adobe InDesign CC 13.1 (Windows)

Related Documents

Preview COVID-19 At-Home Test: Healthcare Provider Instructions for Use
Comprehensive instructions for the Roche COVID-19 At-Home Test, detailing intended use, test procedure, result interpretation, clinical performance, and analytical data for SARS-CoV-2 antigen detection. Includes warnings, precautions, and limitations.
Preview cobas liat SARS-CoV-2 v2 Nucleic Acid Test: CLIA Waiver Decision Summary
Summary of the CLIA waiver approval determination for the cobas liat SARS-CoV-2 v2 nucleic acid test by Roche Molecular Systems, Inc. This document details the test's performance characteristics, system components, and validation studies, including flex studies, comparison studies, and operator proficiency, supporting its designation as CLIA waived.
Preview Roche cobas Respiratory 4-flex FDA Clearance for Multi-Virus Detection
Roche announces FDA 510(k) clearance for its cobas Respiratory 4-flex assay, a TAGS technology-powered diagnostic test detecting SARS-CoV-2, Influenza A, Influenza B, and RSV, enhancing respiratory testing efficiency for laboratories.
Preview Sepsis and AMR: Diagnostic Solutions Empowering Clinicians | Roche
Explore how Roche's diagnostic solutions, focusing on biomarkers like PCT and IL-6, empower clinicians to effectively tackle the coupled threats of sepsis and antimicrobial resistance (AMR).
Preview Roche Diagnostics Showcases Innovation at ADLM 2025 | Science-Driven Healthcare Solutions
Roche Diagnostics highlights its latest innovations in diagnostics, including AI solutions, cardiovascular and cervical cancer screening advancements, and new platform technologies at ADLM 2025 in Chicago. Learn about their commitment to improving patient outcomes and healthcare delivery.
Preview Richeal Cline Biography and Roche Diagnostics Overview
Profile of Richeal Cline, Head of Diagnostics Global Operations and Global Head of Quality & Regulatory at Roche Diagnostics, along with an overview of Roche's leadership in healthcare.
Preview Cost Effectiveness of PD-L1 Testing: IVDs vs. LDTs in NSCLC
An overview of a 2022 academic study comparing the cost-effectiveness of In Vitro Diagnostics (IVDs) and Lab-Developed Tests (LDTs) for PD-L1 testing in non-small cell lung cancer (NSCLC), highlighting accuracy, patient outcomes, and cost benefits.
Preview v-TAC Standalone Software User Guide
User guide for the v-TAC Standalone software, detailing its features, operation, and safety information for in vitro diagnostic use.